Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Treatment in Bladder Cancer
NCT02489890Phase 2Active, not recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Feb 2016
- Primary completion
- Jul 2025
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
A Phase 2 trial of unmodified CIK in bladder carcinoma, sponsored by Changzhou First People's Hospital. Started Feb 2016; status: active, not recruiting.
02
Drugs
unmodified CIK
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT02489890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489890.